Aktuelle Dermatologie, Table of Contents Aktuelle Dermatologie 2016; 42(12): 493DOI: 10.1055/s-0042-117796 Editorial © Georg Thieme Verlag KG Stuttgart · New YorkPruritus und NeurodermitisPruritus and Atopic Dermatitis C. Bayerl Recommend Article Abstract Full Text References Literatur 1 Hanifin J, Chan SC, Cheng JB et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996; 107: 51-56 2 Griffiths CE, van Leent EJ, Gilbert M et al. Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis. Br J Dermatol 2002; 147: 299-307 3 Stein Fold LF, Spelman L, Spellman MC et al. A Phase 2, randomized, controlled, dose-ranging study evaluating crisaborole topical ointment, 0,5 % and 2 % in adolescents with mild to moderate atopic dermatitis. J Drugs Dermatol 2016; 14: 1394-1399 4 Saporito RC, Cohen DJ. Apremilast use for moderate-to-severe atopic dermatitis in pediatric patients. Case Report Dermatology 2016; 8: 179-184
